Wall Street brokerages expect Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) to report ($0.87) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Anthera Pharmaceuticals’ earnings, with estimates ranging from ($1.03) to ($0.71). Anthera Pharmaceuticals reported earnings per share of ($2.88) during the same quarter last year, which would indicate a positive year over year growth rate of 69.8%. The company is scheduled to report its next quarterly earnings report on Monday, February 26th.

According to Zacks, analysts expect that Anthera Pharmaceuticals will report full year earnings of ($3.34) per share for the current financial year, with EPS estimates ranging from ($3.61) to ($3.07). For the next year, analysts anticipate that the business will report earnings of ($3.49) per share, with EPS estimates ranging from ($3.92) to ($2.68). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Anthera Pharmaceuticals.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.32. During the same quarter last year, the company posted ($4.85) earnings per share.

Several equities analysts have recently issued reports on ANTH shares. Jefferies Group LLC reissued a “hold” rating and set a $1.75 price target (down previously from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. Zacks Investment Research downgraded shares of Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $5.11.

WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/14/brokerages-expect-anthera-pharmaceuticals-inc-anth-will-post-earnings-of-0-87-per-share.html.

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) traded up $0.03 on Tuesday, hitting $1.89. 476,000 shares of the stock traded hands, compared to its average volume of 330,808. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $20.24.

Several institutional investors and hedge funds have recently modified their holdings of the company. Wedbush Securities Inc. increased its holdings in shares of Anthera Pharmaceuticals by 75.8% in the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 31,800 shares during the period. UBS Group AG grew its stake in shares of Anthera Pharmaceuticals by 9.9% in the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Anthera Pharmaceuticals by 1,376.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares in the last quarter. Institutional investors own 26.10% of the company’s stock.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.